August 15th 2019
Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure. Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced that clinical data from the ongoing phase 2a study of its lead product candidate HepaStem ® in patients with Acute-on-Chronic Liver Failure.
